Here's why the Total Brain (ASX:TTB) share price is rocketing 58% today

The company has announced a data licensing agreement. Here are the details

Child wearing a space helmet and sitting with thumbs up next to two toy rockets on a desk with a computer, keyboard and mouse.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Total Brain Ltd (ASX: TTB) share price is rebounding after hitting an all-time low of 9.4 cents on Friday. This comes after the digital mental health software-as-a-service (SaaS) company announced a data licensing agreement that has excited investors.

At the time of writing, Total Brain shares are surging a whopping 57.89% to 15 cents apiece.

Total Brain secures data licensing agreement

In a statement to the ASX, Total Brain advised it has entered into a perpetual, non-exclusive licence with Janssen Research & Development, LLC.

Founded in 2001, Janssen supports the pharmaceutical business of global healthcare behemoth, Johnson & Johnson.

Janssen specialises in researching, developing, and producing medicines for a range of diseases. This relates to areas such as cardiovascular and metabolism, immunology, infectious diseases and vaccines, neuroscience, oncology, and pulmonary hypertension.

Under the agreement, Janssen will have access to Total Brain's iSPOT-D (International Study to Predict Optimized Treatment for Depression) research data. The licensing deal is effective immediately.

As such, Total Brain will receive a one-off licence fee of US$2.2 million within the next 90 days.

This will indeed boost the company's cash runway significantly for research activities beyond the June 2022 quarter. Previously, Total Brain had $2.6 million at the end of September 2021.

More on Total Brain

Based in San Francisco and Sydney, Total Brain has developed the world's first mental health self-monitoring and self-care platform.

Its SaaS platform has helped more than 1 million users scientifically measure and optimise their brain capacities while managing the risk of common mental conditions.

These benefits for employers, large organisations, and insurers have translated to productivity improvements and healthcare cost reduction.

Total Brain share price snapshot

Over the past 12 months, the Total Brain share price has lost around 52%. It is also down roughly 53% this year to date. It is a stark contrast from when the company's shares reached a 52-week high of 50.5 cents in January 2021.

On valuation grounds, Total Brain presides a market capitalisation of about $17.34 million, with 133.39 million shares outstanding.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned.

More on Healthcare Shares

A woman with strawberry blonde hair has a huge smile on her face and fist pumps the air having seen good news on her phone.
Healthcare Shares

Why are Mesoblast shares jumping 10% to a 52-week high?

This biotech is hitting new highs on Friday. Let's find out why.

Read more »

a group of surgeons in full surgery dress including masks, gloves and head coverings stands together with arms folded and smiling eyes as if happy with the outcome of their efforts.
Healthcare Shares

Ansell shares tumble to a 3-month low. Is this a buying opportunity?

Ansell shares have slid to a 3-month low. Could oversold signals point to a buying opportunity for long-term investors?

Read more »

Female scientist working in a laboratory.
Healthcare Shares

These three biotechs show how the sector can produce huge outsized gains, but are they still good value?

These drug developers' shares are trading near 12-month highs.

Read more »

A medical specialist holds a red heart connected via technology and artificial intelligence.
Healthcare Shares

This biotech is approaching 20-bagger status within a year and the good news continues to come

This company has just won approval to go ahead with a key clinical trial.

Read more »

An investor sits at a table in front of her laptop with a party hat on her head and a cake next to her symbolising new year's eve but the 4DS Memory share price is plunging so she looks very disappointed and depressed
Healthcare Shares

$5 billion ASX 200 healthcare stock tumbling on CEO exit

Investors are bidding down the ASX 200 healthcare giant on Thursday. Let’s see why.

Read more »

woman testing substance in laboratory dish, csl share price
Share Market News

After a 73% surge this ASX healthcare share looks far from done

Brokers are upbeat, and some see possible gains of 90% in 2026.

Read more »

Female scientist working in a laboratory.
Healthcare Shares

Which biotech's shares are surging higher on US patent news?

Investors like what they see from this drug company.

Read more »

Medical workers examine an xray or scan in a hospital laboratory.
Healthcare Shares

This biotech company's shares are on a tear – again – after another contract win

A new contract with a prestigious US institution spells good news for shareholders.

Read more »